However, CTL activity against PANC-1 cells induced by OPK/TGF-β was significantly reduced compared to OPK/Mock (Fig. 7A and B), suggesting that the DC/tumor-derived active form of TGF-β1 reduced the efficacy of fusion-based cancer vaccines in vitro. The gene discussed is TGFB1; the disease is cancer.